Notes
US dollars
willingness-to-pay
Reference
Zhou J, et al. Cost-effectiveness analysis of treatments for metastatic pancreatic cancer based on PRODIGE and MPACT trials. Tumori : 5 Apr 2016. Available from: URL: http://doi.org/10.5301/tj.5000499
Rights and permissions
About this article
Cite this article
GEM-N more cost effective than FOLFIRINOX in China. PharmacoEcon Outcomes News 751, 14 (2016). https://doi.org/10.1007/s40274-016-2974-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-016-2974-8